Omega Therapeutics (OMGA) Stock Forecast, Price Target & Predictions
OMGA Stock Forecast
Omega Therapeutics stock forecast is as follows: an average price target of $9.00 (represents a 561.76% upside from OMGA’s last price of $1.36) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.
OMGA Price Target
The average price target for Omega Therapeutics (OMGA) is $9.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $11.00 to $7.00. This represents a potential 561.76% upside from OMGA's last price of $1.36.
OMGA Analyst Ratings
According to 1 Wall Street analysts, Omega Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for OMGA stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Omega Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 03, 2024 | Edward Tenthoff | Piper Sandler | $9.00 | $3.01 | 199.00% | 561.76% |
| Apr 01, 2024 | Keay Nakae | Loop Capital Markets | $7.00 | $3.65 | 91.78% | 414.71% |
| Dec 08, 2022 | - | H.C. Wainwright | $11.00 | $6.30 | 74.60% | 708.82% |
The latest Omega Therapeutics stock forecast, released on Apr 03, 2024 by Edward Tenthoff from Piper Sandler, set a price target of $9.00, which represents a 199.00% increase from the stock price at the time of the forecast ($3.01), and a 561.76% increase from OMGA last price ($1.36).
Omega Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $8.00 |
| Last Closing Price | $1.36 | $1.36 | $1.36 |
| Upside/Downside | -100.00% | -100.00% | 488.24% |
In the current month, the average price target of Omega Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Omega Therapeutics's last price of $1.36. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 15, 2024 | Wedbush | Buy | Buy | Hold |
| Aug 15, 2024 | Raymond James | Underperform | Underperform | Hold |
| Jun 18, 2024 | Piper Sandler | Underperform | Underperform | Hold |
| Jun 18, 2024 | Raymond James | Buy | Buy | Hold |
| Jun 18, 2024 | Raymond James | - | Outperform | Initialise |
| May 07, 2024 | Chardan Capital | Underperform | Underperform | Hold |
| May 07, 2024 | Piper Sandler | Buy | Buy | Hold |
| Apr 03, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Apr 01, 2024 | Chardan Capital | Buy | Buy | Hold |
Omega Therapeutics's last stock rating was published by Wedbush on Aug 15, 2024. The company gave OMGA a "Buy" rating, the same as its previous rate.
Omega Therapeutics Financial Forecast
Omega Therapeutics Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $831.00K | $759.00K | $516.00K | $735.00K | $595.00K | - | $268.00K |
| Avg Forecast | $780.00K | $780.00K | $650.00K | $683.33K | $1.20M | $1.20M | $956.14K | $1.16M | $450.00K | $442.86K | $378.57K | $314.29K | $257.50K | $101.20K | $51.50K | $338.53K |
| High Forecast | $780.00K | $780.00K | $650.00K | $683.33K | $1.20M | $2.30M | $956.14K | $1.16M | $483.87K | $442.86K | $378.57K | $314.29K | $257.50K | $101.20K | $51.50K | $406.23K |
| Low Forecast | $780.00K | $780.00K | $650.00K | $683.33K | $1.20M | $481.77K | $956.14K | $1.16M | $411.29K | $442.86K | $378.57K | $314.29K | $257.50K | $101.20K | $51.50K | $270.82K |
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 18 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.88% | 2.00% | 1.64% | 2.85% | 5.88% | - | 0.79% |
Omega Therapeutics's average Quarter revenue forecast for Dec 23 based on 3 analysts is $450.00K, with a low forecast of $411.29K, and a high forecast of $483.87K. OMGA's average Quarter revenue forecast represents a -45.85% decrease compared to the company's last Quarter revenue of $831.00K (Sep 23).
Omega Therapeutics EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 18 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-22.90M | $-30.84M | $-25.82M | $-30.97M | $-25.59M | - | $-19.63M |
| Avg Forecast | $-156.00K | $-156.00K | $-130.00K | $-136.67K | $-240.88K | $-240.88K | $-191.23K | $-232.86K | $-90.00K | $-88.57K | $-75.71K | $-62.86K | $-51.50K | $-20.24K | $-10.30K | $-24.80M |
| High Forecast | $-156.00K | $-156.00K | $-130.00K | $-136.67K | $-240.88K | $-96.35K | $-191.23K | $-232.86K | $-82.26K | $-88.57K | $-75.71K | $-62.86K | $-51.50K | $-20.24K | $-10.30K | $-19.84M |
| Low Forecast | $-156.00K | $-156.00K | $-130.00K | $-136.67K | $-240.88K | $-460.57K | $-191.23K | $-232.86K | $-96.77K | $-88.57K | $-75.71K | $-62.86K | $-51.50K | $-20.24K | $-10.30K | $-29.76M |
| Surprise % | - | - | - | - | - | - | - | - | - | 258.58% | 407.32% | 410.74% | 601.31% | 1264.44% | - | 0.79% |
undefined analysts predict OMGA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Omega Therapeutics's previous annual EBITDA (undefined) of $NaN.
Omega Therapeutics Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 18 |
| Net Income | - | - | - | - | - | - | - | - | - | $-22.25M | $-29.69M | $-24.06M | $-30.68M | $-25.61M | - | $-20.37M |
| Avg Forecast | $-12.68M | $-12.46M | $-13.42M | $-12.78M | $-12.84M | $-15.44M | $-20.15M | $-18.36M | $-24.73M | $-29.15M | $-27.42M | $-32.38M | $-34.30M | $-32.68M | $-31.16M | $-25.47M |
| High Forecast | $-12.68M | $-12.46M | $-13.42M | $-12.78M | $-12.84M | $-11.95M | $-20.15M | $-18.36M | $-24.19M | $-29.15M | $-27.42M | $-32.38M | $-34.30M | $-32.68M | $-31.16M | $-20.38M |
| Low Forecast | $-12.68M | $-12.46M | $-13.42M | $-12.78M | $-12.84M | $-19.93M | $-20.15M | $-18.36M | $-25.80M | $-29.15M | $-27.42M | $-32.38M | $-34.30M | $-32.68M | $-31.16M | $-30.56M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.76% | 1.08% | 0.74% | 0.89% | 0.78% | - | 0.80% |
Omega Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. OMGA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Omega Therapeutics SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 18 |
| SG&A | - | - | - | - | - | - | - | - | - | $7.87M | $6.21M | $5.95M | $5.36M | $5.20M | - | $5.41M |
| Avg Forecast | $20.92M | $20.92M | $17.43M | $18.33M | $32.30M | $32.30M | $25.64M | $31.23M | $12.07M | $11.88M | $10.15M | $8.43M | $6.91M | $2.71M | $1.38M | $9.08M |
| High Forecast | $20.92M | $20.92M | $17.43M | $18.33M | $32.30M | $61.76M | $25.64M | $31.23M | $12.98M | $11.88M | $10.15M | $8.43M | $6.91M | $2.71M | $1.38M | $10.90M |
| Low Forecast | $20.92M | $20.92M | $17.43M | $18.33M | $32.30M | $12.92M | $25.64M | $31.23M | $11.03M | $11.88M | $10.15M | $8.43M | $6.91M | $2.71M | $1.38M | $7.26M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.66% | 0.61% | 0.71% | 0.78% | 1.92% | - | 0.60% |
Omega Therapeutics's average Quarter SG&A projection for Dec 23 is $12.07M, based on 3 Wall Street analysts, with a range of $11.03M to $12.98M. The forecast indicates a 53.37% rise compared to OMGA last annual SG&A of $7.87M (Sep 23).
Omega Therapeutics EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 2 | 4 | 2 | 1 | 3 | 1 | 1 | 1 | 1 | 1 | - | 18 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.40 | $-0.54 | $-0.48 | $-0.64 | $-0.54 | - | $-0.43 |
| Avg Forecast | $-0.23 | $-0.23 | $-0.24 | $-0.23 | $-0.23 | $-0.28 | $-0.37 | $-0.33 | $-0.45 | $-0.53 | $-0.50 | $-0.59 | $-0.62 | $-0.59 | $-0.56 | $-0.57 |
| High Forecast | $-0.23 | $-0.23 | $-0.24 | $-0.23 | $-0.23 | $-0.22 | $-0.37 | $-0.33 | $-0.44 | $-0.53 | $-0.50 | $-0.59 | $-0.62 | $-0.59 | $-0.56 | $-0.50 |
| Low Forecast | $-0.23 | $-0.23 | $-0.24 | $-0.23 | $-0.23 | $-0.36 | $-0.37 | $-0.33 | $-0.47 | $-0.53 | $-0.50 | $-0.59 | $-0.62 | $-0.59 | $-0.56 | $-0.62 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.76% | 1.09% | 0.82% | 1.03% | 0.91% | - | 0.76% |
According to undefined Wall Street analysts, Omega Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to OMGA previous annual EPS of $NaN (undefined).
Omega Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals | $1.50 | $24.75 | 1550.00% | Buy |
| AVTE | Aerovate Therapeutics | $1.91 | $13.00 | 580.63% | Hold |
| OMGA | Omega Therapeutics | $1.36 | $9.00 | 561.76% | Buy |
| PEPG | PepGen | $9.12 | $29.50 | 223.46% | Buy |
| CMPX | Compass Therapeutics | $1.66 | $5.00 | 201.20% | Buy |
| MLYS | Mineralys Therapeutics | $11.98 | $30.00 | 150.42% | Buy |
| GPCR | Structure Therapeutics | $38.44 | $86.00 | 123.73% | Buy |
| OLMA | Olema Pharmaceuticals | $12.27 | $27.00 | 120.05% | Buy |
| LRMR | Larimar Therapeutics | $6.81 | $14.50 | 112.92% | Buy |
| PHVS | Pharvaris | $20.25 | $38.50 | 90.12% | Buy |
| ELYM | Eliem Therapeutics | $7.96 | $13.00 | 63.32% | Buy |
| MLTX | MoonLake Immunotherapeutics | $50.99 | $79.33 | 55.58% | Buy |
| ELVN | Enliven Therapeutics | $21.47 | $33.00 | 53.70% | Buy |
| CNTA | Centessa Pharmaceuticals | $16.28 | $19.50 | 19.78% | Buy |
OMGA Forecast FAQ
Is Omega Therapeutics a good buy?
Yes, according to 1 Wall Street analysts, Omega Therapeutics (OMGA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of OMGA's total ratings.
What is OMGA's price target?
Omega Therapeutics (OMGA) average price target is $9 with a range of $7 to $11, implying a 561.76% from its last price of $1.36. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Omega Therapeutics stock go up soon?
According to Wall Street analysts' prediction for OMGA stock, the company can go up by 561.76% (from the last price of $1.36 to the average price target of $9), up by 708.82% based on the highest stock price target, and up by 414.71% based on the lowest stock price target.
Can Omega Therapeutics stock reach $2?
OMGA's average twelve months analyst stock price target of $9 supports the claim that Omega Therapeutics can reach $2 in the near future.
What are Omega Therapeutics's analysts' financial forecasts?
Omega Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $4.53M (high $5.63M, low $3.81M), average EBITDA is $-906K (high $-761K, low $-1.126M), average net income is $-66.789M (high $-63.302M, low $-71.272M), average SG&A $121.48M (high $150.94M, low $102.09M), and average EPS is $-1.211 (high $-1.148, low $-1.292). OMGA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $2.89M (high $2.89M, low $2.89M), average EBITDA is $-579K (high $-579K, low $-579K), average net income is $-51.345M (high $-51.345M, low $-51.345M), average SG&A $77.6M (high $77.6M, low $77.6M), and average EPS is $-0.931 (high $-0.931, low $-0.931).
Did the OMGA's actual financial results beat the analysts' financial forecasts?
Based on Omega Therapeutics's last annual report (Dec 2023), the company's revenue was $3.09M, beating the average analysts forecast of $1.59M by 95.12%. Apple's EBITDA was $-100M, beating the average prediction of $-317K by 31514.01%. The company's net income was $-97.428M, missing the average estimation of $-114M by -14.29%. Apple's SG&A was $26.19M, missing the average forecast of $42.53M by -38.43%. Lastly, the company's EPS was $-1.8, missing the average prediction of $-2.061 by -12.67%. In terms of the last quarterly report (Sep 2023), Omega Therapeutics's revenue was $831K, beating the average analysts' forecast of $442.86K by 87.65%. The company's EBITDA was $-22.903M, beating the average prediction of $-88.571K by 25758.35%. Omega Therapeutics's net income was $-22.248M, missing the average estimation of $-29.151M by -23.68%. The company's SG&A was $7.87M, missing the average forecast of $11.88M by -33.75%. Lastly, the company's EPS was $-0.4, missing the average prediction of $-0.529 by -24.32%